Hikal starts construction of multiproduct API plant

Published: 28-Oct-2011
Manufacturing Ingredients

Will be operational by June 2012

Hikal, an Indian supplier of active ingredients and intermediates to the pharmaceutical industry, has started construction of a new multipurpose, multiproduct API plant, which will be operational by June 2012.

The flexible plant will be able to manufacture four APIs simultaneously under GMP and consists of two parallel streams running simultaneously with quick changeover capability.

The plant will also be able to accommodate 32 reactors with capacities ranging from 6m3 to 10m3, resulting in a total reactor volume of approximately 300m3.

A wide range of reactions will be carried out in the new plant, including nitration, liquid phase Oppenauer oxidation, Swern oxidation, Suzuki reaction, chiral synthesis, Mannich reaction, Friedel Craft reactions and more.

The firm says the reactors will be a combination of stainless steel and glass lined. Equipment for isolation and drying such as agitated nutsch filters, centrifuges and various types of dryers will also be installed.

Hikal has five manufacturing facilities in India at Maharashtra (Taloja and Mahad), Gujarat (Panoli) and Bangalore (Jigani), including an r&D centre and a dedicated contract research facility, Acoris Research, in Pune.

See more

You may also like

Ingredients

Hikal completes third US FDA audit in Bangalore

Read more
Indian ingredients manufacturer will ramp up new products under validation

Trending Articles

  1. Agility, scale and trust: the outsourcing model driving pharma forward Outsourcing in the pharmaceutical industry has long been viewed as a matter of convenience and a way to ease short-term capacity pressures or delay the decision to invest in costly new facilities. That framing no longer fits
  2. RION engages Lonza to scale manufacturing exosome based therapeutics Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions
  3. Gerresheimer boosts Wertheim site with new production facility The new production hall will focus on RTF vials and innovative EZ-fill Smart packaging platform, with a total investment volume of around EUR €30 million
  4. Starlab launches the first TipOne racks made with recycled TipOne plastic The circle is finally complete by turning plastic lab waste back into high-quality lab products
  5. Rousselot to unveil gelatin prototypes for innovative medical device development at COMPAMED 2025 Rousselot, Darling Ingredients’ premier collagen and gelatin brand, will participate in COMPAMED 2025, November 17-20, 2025, in Düsseldorf, Hall 8, Booth AK14

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Ingredients

Hikal completes third US FDA audit in Bangalore

Indian ingredients manufacturer will ramp up new products under validation
Media

Acoris and c-LEcta to develop synthetic routes for chiral compounds

<p>Acoris Research, a subsidiary of Hikal, and c-LEcta, a German industrial biotech company, are to collaborate on developing synthetic routes for chiral compounds. The partnership combines the expertise of Acoris in process development and small-scale manufacturing with the biocatalysis technologies of c-LEcta.</p>
Ingredients

Hikal signs API contract manufacturing agreement with Pfizer

<p>Indian outsourcing company Hikal has completed a contract manufacturing agreement for supply of active pharmaceutical ingredients (APIs) with Pfizer. Terms of the agreement were not disclosed.</p>
Manufacturing

Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia

Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Decoding your personal health ecosystem: the power of microbiome diagnostics and nutraceuticals

People often talk about a “gut instinct” or a “gut feeling.” Until recently, though, actually discussing digestive health might have seemed unusual, suggests Christina Casén, Senior Vice President, Clinical and Medical Affairs at Genetic Analysis AS
Manufacturing

Navigating SOE compliance: how to strengthen organic enforcement within your organisation

Part I of NSF’s webinar series explores strategies to meet rising regulatory demands, reduce fraud, and promote ethical practices
Manufacturing

Exploring Ireland’s thriving life sciences sector

NSF highlights its pivotal role in one of the world’s leading hubs for pharma and medical device manufacturing
Subscribe now